Delta-Fly Pharma, Inc. (4598) Stock Statistics & Valuation Metrics

Delta-Fly Pharma, Inc. has a market cap or net worth of ¥6.32B. The enterprise value is ¥5.68B.

Delta-Fly Pharma, Inc. has 12,159,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

Delta-Fly Pharma, Inc.’s return on equity (ROE) is -6.20 and return on invested capital (ROIC) is -615.82%.

The current PE Ratio of Delta-Fly Pharma, Inc. is ―. Delta-Fly Pharma, Inc.’s PEG ratio is 1.82.

In the last 12 months, Delta-Fly Pharma, Inc. had revenue of 0.00 and earned -1.72B in profits. Earnings per share was -195.58.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Delta-Fly Pharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Delta-Fly Pharma, Inc. upcoming earnings date is Feb 13, 2026, TBA (Confirmed).

Delta-Fly Pharma, Inc. as a current ratio of 2.52, with Debt / Equity ratio of 0.00%

In the past 12 months, Delta-Fly Pharma, Inc. has paid 2.50M in taxes.

Delta-Fly Pharma, Inc. EV to EBITDA ratio is -2.75, with an EV/FCF ratio of -2.57.

Delta-Fly Pharma, Inc. has ¥730.32M in cash and marketable securities with ¥0.00 in debt, giving a net cash position of ¥730.32M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Delta-Fly Pharma, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―